Australian Life Scientist Journalist Tim Dean investigates Starpharma’s pre-clinical studies on popular chemotherapy drug, docataxel:  ‘Chemotherapy drugs are big business, and Melbourne-based Starpharma is looking to get involved by applying its dendrimer technology to reformulate and improve leading therapies.’

Starpharma today announced the nomination of leading anti-cancer drug docetaxel as a lead candidate in its cancer drug delivery program following encouraging early results.

• Starpharma’s dendrimers demonstrate improvements in multibillion dollar chemotherapy drug, docetaxel;
• Water solubility improved more than 2000-fold, potentially reducing serious side effects;
• Starpharma to advance a dendrimer-docetaxel formulation as a lead candidate in its drug delivery cancer program.

Starpharma invites you to listen to an audio broadcast with Chief Executive Officer Dr Jackie Fairley, regarding the successful results of the major phase 2 clinical study that demonstrated efficacy of VivaGel^® for the treatment of bacterial vaginosis (BV).

To listen to the Boardroom Radio audio broadcast please click here. 

Starpharma today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel^® for the treatment of bacterial vaginosis (BV).

 Key Points:

•  VivaGel^® meets primary endpoint, demonstrating significant efficacy for treatment of BV
• VivaGel^® expected to avoid many shortcomings of existing therapies

Starpharma today announced that it has signed a licence agreement with Okamoto Industries Inc  in relation to the VivaGel^®-coated condom for the Japanese market.  Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

The cash balance at 31 March 2011 was $20.1m compared to $19.7m at 31 December 2010.

The Operating & Investing cash outflow of $1.6m for the quarter includes the costs of the fully enrolled phase 2 study assessing VivaGel^® as a treatment for bacterial vaginosis. Financing cash inflows of $2.0m included proceeds from the exercise of share options during the quarter.

Starpharma today announced it had completed enrolment and all patient follow-up visits in its phase 2 study of VivaGel^® for the treatment of bacterial vaginosis (BV).

This study investigated the effectiveness of VivaGel^® administered once daily for seven days in the treatment of BV and enrolled 132 participants in the US. Data is now being processed and results will be available in the second quarter of this year.

Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar^® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates.